BTK inhibitor study for chronic lymphocytic leukemia
Treatments studied
Part of Blood & lymphatic, Cancer clinical trials.
This study looks at how well BTK inhibitors work in people with chronic lymphocytic leukemia (CLL) in real-world settings. It includes both new patients and those who have had treatment before.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be 18 years or older
- You must have chronic lymphocytic leukemia (CLL) that needs treatment
- You can be starting treatment for the first time or have had treatment before
- You must have taken or are currently taking a BTK inhibitor for at least 3 months
- You must have had at least one check-up while on the BTK inhibitor
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug, BGB-16673, for people with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) who have already tried two types of treatments (BTK and BCL2 inhibitors). The goal is to see if this new drug works better than other available treatments chosen by the doctor.
This trial tests a new approach for people newly diagnosed with high-risk CLL or SLL. It combines your own immune cells (CAR-T cells) with a targeted pill (BTK inhibitor) to try to attack the cancer more effectively. It may be an option if you have certain high-risk genetic features and haven't had prior chemotherapy.
This study compares two oral targeted therapies, rocbrutinib and pirtobrutinib, for people with CLL or SLL whose disease has come back or stopped responding after treatment with a covalent BTK inhibitor (like ibrutinib). The goal is to see which drug works better and has fewer side effects.
This study looks at how BTK inhibitors (a targeted therapy) are currently used in China for people with CLL or SLL. It aims to understand real-world treatment patterns and outcomes.
This study follows patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)—blood cancers—who have been taking a type of targeted drug called a BTK inhibitor for at least 2 years. Researchers want to understand what happens to these patients' cancer and health after they stop taking this medication.
This study looks at CLL patients who are taking or may take a BTK degrader (a newer type of targeted therapy) to find out what factors influence how well the treatment works. It aims to help doctors understand who benefits most from this approach.
Hear when a new CLL trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.